Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy.

ABSTRACT:

Background

A favorable model for predicting disease-free survival (DFS) and stratifying prognostic risk in breast cancer (BC) treated with neoadjuvant chemotherapy (NAC) is lacking. The aim of the current study was to formulate an excellent model specially for predicting prognosis in these patients.

Patients and methods

Between January 2012 and December 2015, 749 early-stage BC patients who received NAC in Xijing hospital were included. Patients were randomly assigned to a training cohort (n = 563) and an independent cohort (n = 186). A prognostic model was created and subsequently validated. Predictive performance and discrimination were further measured and compared with other models.

Results

Clinical American Joint Committee on Cancer stage, grade, estrogen recepto

SUBMITTER: Hou N 

PROVIDER: S-EPMC8455687 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature